English
Français
Deutsch
Italiano
Русский
Español
हिन्दी
简体中文
한국어
日本語
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Citi’s SMID Call Series 2025 October 2, 2025 1:00 PM EDT
Company Participants
Zachary Roberts – Executive VP of Research & Development and Chief Medical Officer
Conference Call Participants
Samantha Semenkow – Citigroup Inc., Research Division
Presentation
Samantha Semenkow
Citigroup Inc., Research Division
Good afternoon, and thank you for joining. I’m Sam Semenkow, one of the senior biotech analysts here at Citi, and it’s my pleasure to be hosting Allogene’s Executive Vice President and CMO, Zach Roberts, as a part of Citi’s SMID Biotech C-suite virtual fireside chat series. Zach, welcome, and thank you so much for joining us today.
Zachary Roberts
Executive VP of Research & Development and Chief Medical Officer
Thanks so much for having me, Sam.
Samantha Semenkow
Citigroup Inc., Research Division
If anyone live on the call has any questions during the session, please go ahead and e-mail them to me directly at [email protected], and I’d be happy to ask them on your behalf.
Question-and-Answer Session
Samantha Semenkow
Citigroup Inc., Research Division
So Zach, why don’t we sort of jump right in? Maybe at a high level, let’s just talk about Allogene’s pipeline and where you are today as a company.
Zachary Roberts
Executive VP of Research & Development and Chief Medical Officer
Sure. So Allogene was founded in 2018. We have been, since the beginning, a company focused on allogeneic cell therapies, initially for oncology indications, and now we’ve recently expanded into autoimmune indications as well. We currently have 3 clinical programs that are ongoing. We’ve got our lead pivotal program with its CD19 off-the-shelf allogeneic CAR T product called cema-cel. And this is being developed in a very unique indication in what we call frontline consolidation for large B-cell lymphoma. And we’ll have plenty of time, I think, during the call to talk more about this ALPHA3 trial. So I’ll save that for later.
Read the full article here
